Cargando…
Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?
BACKGROUND AND OBJECTIVES: Pure relapsing short myelitis with clinical and paraclinical features suggesting multiple sclerosis (MS) has been described recently. Here, we evaluated the existence of this potential new form of MS by retrospectively searching for similar cases in the databases of the Fr...
Autores principales: | Poullet, Zélia, Pique, Julie, Maarouf, Adil, Boutiere, Clemence, Rico, Audrey, Demortiere, Sarah, Durozard, Pierre, Papeix, Caroline, Maillart, Elisabeth, Collongues, Nicolas, Ayrignac, Xavier, Zephir, Helene, Deschamps, Romain, Ciron, Jonathan, Pelletier, Jean, Marignier, Romain, Audoin, Bertrand |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128038/ https://www.ncbi.nlm.nih.gov/pubmed/35473885 http://dx.doi.org/10.1212/NXI.0000000000001167 |
Ejemplares similares
-
Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
por: Demortiere, Sarah, et al.
Publicado: (2023) -
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases
por: Avouac, Alexandre, et al.
Publicado: (2021) -
Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab
por: Perriguey, Marine, et al.
Publicado: (2021) -
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
por: Maarouf, Adil, et al.
Publicado: (2020) -
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
por: Claverie, Roxane, et al.
Publicado: (2023)